Impact of tislelizumab plus chemotherapy versus placebo plus chemotherapy on patient-reported symptoms and overall survival (OS) by programmed death-ligand 1 (PD-L1) expression in advanced or metastatic esophageal squamous cell carcinoma (ESCC): A post hoc analysis of the RATIONALE-306 trial.

被引：0

作者：

Yoon, Harry H.

Xu, Jianming

Kato, Ken

Pan, Yueyin

Park, Sook Ryun

Shen, Lin

Van Cutsem, Eric

Jimenez-Fonseca, Paula

Barnes, Frederick

Sun, Tianmo

Barnes, Gisoo

Victor, Timothy

机构：

[1] Mayo Clin Rochester, Rochester, MN USA

[2] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China

[3] Natl Canc Ctr Hosp, Dept Head & Neck Esophageal Med Oncol, Chuo City, Tokyo, Japan

[4] Anhui Prov Hosp, Hefei, Anhui, Peoples R China

[5] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

[6] Beijing Canc Hosp, Beijing, Peoples R China

[7] Fdn Med Inc, Cambridge, MA USA

[8] Cent Univ Hosp Asturias, ISPA, Oviedo, Spain

[9] BeiGene USA Inc, San Mateo, CA USA

[10] BeiGene Beijing Co Ltd, Beijing, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期

关键词：

D O I：

10.1200/JCO.2025.43.4_suppl.366

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：366 / 366

页数：1

共 21 条

[1] Impact of tislelizumab plus chemotherapy versus placebo plus chemotherapy on patient-reported symptoms and disease progression by programmed death-ligand 1 expression in gastroesophageal adenocarcinoma: A post hoc analysis of the RATIONALE-305 trial.
Cruz-Correa, Marcia
Oh, Do-Youn
Xu, Rui-Hua
Moehler, Markus H.
Kato, Ken
Barnes, Frederick
Xu, Yaling
Sheng, Tao
Barnes, Gisoo
Victor, Timothy
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 365 - 365
[2] First-Line Tislelizumab Plus Chemotherapy for Esophageal Squamous Cell Carcinoma with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-306
Xu, Jianming
Kato, Ken
Hubner, Richard
Park, Sook Ryun
Kojima, Takashi
Ishihara, Ryu
Wyrwicz, Lucjan
Van Cutsem, Eric
Jimenez-Fonseca, Paula
Wu, Hongqian
Wang, Lei
Yan, Sebastian
Shi, Jingwen
Kadva, Alysha
Yoon, Harry H.
ADVANCES IN THERAPY, 2025, : 2269 - 2284
[3] Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in advanced or metastatic esophageal squamous cell carcinoma (ESCC): PD-L1 biomarker analysis from RATIONALE-306
Raymond, E.
Xu, J.
Kato, K.
Hubner, R.
Shu, Y.
Park, S. R.
Kojima, T.
Wyrwicz, L. S.
Tougeron, D.
Geboes, K.
Van Cutsem, E.
Pazo Cid, R. A.
Zaanan, A.
McLachlan, S-A.
Wu, H.
Shi, J.
Li, L.
Yan, S.
Yoon, H.
ANNALS OF ONCOLOGY, 2024, 35 : S159 - S159
[4] First-line (1L) tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 Japanese subgroup analysis with longer follow-up.
Kojima, Takashi
Ogata, Takashi
Ishihara, Ryu
Hara, Hiroki
Sun, Tianmo
Xu, Sheng
Kato, Ken
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 420 - 420
[5] RATIONALE-306: Randomized, global, placebo-controlled, double-blind phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC)
Yoon, H.
Kato, K.
Raymond, E.
Hubner, R.
Shu, Y.
Pan, Y.
Jiang, Y.
Zhang, J.
Park, S.
Kojima, T.
Lin, C.
Gotovkin, E.
Wyrwicz, L.
Ishihara, R.
Li, L.
Tao, A.
Shi, J.
Wang, L.
Xu, J.
ANNALS OF ONCOLOGY, 2022, 33 : S375 - S375
[6] Response characteristics of tislelizumab (TIS) plus chemotherapy (chemo) in first-line (1L) treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): A post hoc analysis of RATIONALE-306.
Li, Yi
Zhao, Chuanhua
Liu, Rongrui
Xu, Sheng
Miao, Xiaojie
Xu, Jianming
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 413 - 413
[7] Randomized, global, phase III study of tislelizumab (TIS) plus chemotherapy (chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment for advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 update
Hubner, R.
Xu, J.
Kato, K.
Raymond, E.
Shu, Y.
Pan, Y.
Jiang, Y.
Zhang, J.
Park, S. R.
Kojima, T.
Lin, C-Y.
Gotovkin, E.
Wyrwicz, L. S.
Ishihara, R.
Wu, H.
Peng, Y.
Wang, L.
Li, L.
Yoon, H.
ANNALS OF ONCOLOGY, 2023, 34 : S853 - S853
[8] Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): China subgroup analysis
Shu, Yongqian
Pan, Yueyin
Lu, Ping
Jiang, Yi
Zhang, Jingdong
Wu, Xiaohong
Yao, Yuanhu
Shen, Lin
Ba, Yi
He, Zhiyong
Bai, Yuxian
Chen, Jianhua
Yu, Guohua
Peng, Yanyan
Wu, Hongqian
Wang, Lei
Li, Liyun
Xu, Jianming
CANCER RESEARCH, 2023, 83 (08)
[9] Randomized, global, phase 3 study of tislelizumab (TIS) plus chemotherapy (chemo) versus placebo (PBO) plus chemo as first-line (1L) treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Non-Asia subgroup.
Raymond, Eric
Hubner, Richard
Gotovkin, Evgeny
Wyrwicz, Lucjan
Van Cutsem, Eric
Jimenez-Fonseca, Paula
Pazo-Cid, Roberto
Xu, Jianming
Kato, Ken
Tao, Aiyang
Wang, Lei
Peng, Yanyan
Li, Liyun
Yoon, Harry H.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 340 - 340
[10] Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): Minimum 3-year survival follow-up
Yoon, Harry H.
Kato, Ken
Raymond, Eric
Hubner, Richard
Shu, Yongqian
Pan, Yueyin
Jiang, Yi
Zhang, Jingdong
Park, Sook Ryun
Kojima, Takashi
Lin, Chen-Yuan
Wyrwicz, Lucjan S.
Tougeron, David
Ishihara, Ryu
Li, Liyun
Wu, Hongqian
Peng, Yanyan
Yan, Shican
Xu, Jianming
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 →